CLSA Praises Committee Passage of 21st Century Cures Act

H.R. 6 protects FDA user fees from sequestration, boosts biomedical research funding, modernizes life sciences innovation ecosystem

 – MAY 21, 2015 – Todd Gillenwater, Executive Vice President of Advocacy & External Relations at the California Life Sciences Association (CLSA), a non-profit representing more than 750 leading life sciences organizations, issued the following statement regarding today’s unanimous Energy & Commerce Committee passage of the 21st Century Cures Act:

“On behalf of the more than 750 life sciences organizations we represent, the California Life Sciences Association applauds Chairman Fred Upton (R-Mich.), Representative Diana DeGette (D-Colo.) and members of the Committee for leading this thoughtful, bipartisan approach to spurring scientific discovery and biomedical innovation that will provide hope for patients here and around the world for many years to come.

“The 21st Century Cures Act is not only visionary, but critical to ensuring that California and our nation remains the worldwide leader in life sciences research, investment and innovation. CLSA applauds the inclusion of meaningful funding increases and reforms that will boost biomedical research efforts at the National Institutes of Health (NIH), protect FDA user fees from sequestration and streamline and modernize numerous regulatory and delivery mechanisms.

“CLSA looks forward to continue working with Chairman Upton, Representative DeGette, bipartisan members of the Committee, House Leadership and California’s congressional delegation to see this importance piece of legislation signed into law.”

Learn more about the 21st Century Cures initiative.

About California Life Sciences Association (CLSA)
California Life Sciences Association (CLSA) is the leading voice for California’s life sciences sector. We work closely with industry, government, academia and other stakeholders to shape public policy, drive business solutions and grow California’s life sciences innovation ecosystem. CLSA serves over 750 biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors and service providers. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged to create the state’s most influential life sciences advocacy and business leadership organization. Visit CLSA at, and follow us on Twitter @CALifeSciences, Facebook, Instagram, LinkedIn and YouTube.

Will Zasadny
Manager, Communications for CLSA